Generate Biomedicines

Generate Biomedicines: Series C Funding Round

Generate Biomedicines has successfully raised $370M in Series C funding, reaching a valuation of $2B.

Company Overview

Generative biology AI drug discovery

Funding Details

The Series C round was led by Flagship Pioneering, with participation from T. Rowe Price, Fidelity, NVIDIA, Alaska Permanent Fund.

Company Information

• Headquarters: 1 Main Street, Cambridge, MA 02142
• Founded: 2018
• Employees: 200+
• Category: Biotech

Investment

Generate Biomedicines plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• Flagship Pioneering: Verified investor in Series C
• T. Rowe Price: Verified investor in Series C
• Fidelity: Verified investor in Series C
• NVIDIA: Verified investor in Series C
• Alaska Permanent Fund: Verified investor in Series C